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Abstract 
Despite their proven ability for precise and targeted release, nanoplatform systems for 
photocontrolled delivery often face formidable synthetic challenges, in part, due to the paucity of 
advanced linker strategies. Here we report on a novel linker strategy using a thioacetal ortho-
nitrobenzaldehyde (TNB) cage, demonstrating its application for delivery of doxorubicin (Dox) 
in two nanoscale systems. This photocleavable linker, TNB(OH), which presents two identical 
arms, each terminated with a hydroxyl functionality, was prepared in a single step from 6-
nitroveratraldehyde.  TNB(OH) was used to crosslink Dox to a folate receptor (FAR)-targeting 
poly(amidoamine) dendrimer conjugate G5(FA)n=5.4(Dox)m=5.1, and
 
also used to prepare an 
upconversion nanocrystal (UCN) conjugate, UCN-PPIX@(Dox)(G5FA), a larger core/shell 
nanostructure. In this core/shell nanostructure, the UCN core emits UV and visible light 
luminescence upon near IR (NIR) excitation, allowing for the photocleavage of the TNB linker 
as well as the photostimulation of protoporphyrin IX (PPIX) coupled as a cytotoxic 
photosensitizer. Drug release experiments performed in aqueous solutions with long wavelength 
UVA light showed that Dox release occurred rapidly from its TNB linked form or from its 
dendrimer conjugated form with comparable decay kinetics. Cellular toxicity studies in FAR-
overexpressing KB carcinoma cells demonstrated that each nanoconjugate lacked intrinsic 
cytotoxicity until exposed to UVA or NIR (980 nm) (for the UCN nanoconjugate), which 
resulted in induction of potent cytotoxicity. In summary, this new TNB strategy offers synthetic 
convenience in drug conjugation chemistry with the ability for temporal control of drug 
activation at the delivery site. 
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Introduction 
Nanotechnology has played a central role in the rapid advances made recently in the 
development of nanometer-scale constructs as targeted, image-guided and controlled delivery 
platforms.
1-3
 These nanoconstructs have been broadly explored as delivery systems for anticancer 
agents,
4-7
 antibiotics,
8-12
 siRNAs
13, 14
 and therapeutic genes.
15, 16
 They offer a variety of 
physicochemical strategies for payload conjugation that are tailored to specific diseases for 
detection, imaging, and treatment purposes.
2, 17, 18
 However, the effectiveness of each system 
varies significantly as dictated by several design factors. The targeting efficiencies of these 
nanoparticle (NP) constructs are determined by a combination of their physicochemical 
properties including NP type, size and surface chemistry
19, 20
 as well as by the specificity, 
affinity, and multivalency of the ligands conjugated to the NPs which bind to specific disease 
biomarkers.
21-25
 Furthermore, the method of drug conjugation and the design of the linker play a 
critical role in facilitating payload release and for controlling the release such that it occurs 
precisely in the targeted cells and tissues.
4, 11, 16, 26-28
 Here we report a new approach for NP-drug 
conjugation based on a thioacetal photocleavable linker, and discuss its application and 
efficiency for light-controlled doxorubicin (Dox) release in two folate receptor (FAR)-targeted 
delivery systems. 
Linkers are all designed with the purpose of tethering therapeutic molecules to a NP carrier, 
but they vary drastically in the types of conjugation chemistry and therefore in the mechanisms 
they utilize for drug release.
26
 Most of the linker chemistries currently developed for tumor-
targeted nanoconjugates rely on stable but conditionally-cleavable covalent bonds such as 
disulfide,
29
 ester,
30
 amide (cis-aconityl
31
), oxime,
32
 and peptide (PVGLIG
33
). Each of these is 
designed to be cleaved selectively in response to an endogenous factor and/or under a 
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pathologically associated condition such as through a thiol/disulfide exchange (glutathione 
[GSH]cellular = 2–10 mM),
29
 low pH (5.5–6.5 in endosomes, lysosomes), overexpressed proteases 
(matrix metalloproteinases),
33, 34
 hypoxia,
35
 and the presence of various tumor biomarkers.
26
 In 
addition, other distinct linker types have also been developed for active control of payload 
release with an exogenous stimulus through photodynamic,
36
 photothermal,
37, 38
 sonodynamic,
39
 
or light activation.
5, 6, 28, 40
 Among such exogenous stimuli, use of light offers unique advantages 
due to the availability of various light sources, the higher degree of spatial resolution,
8, 16, 41
 and 
proven clinical utility.
42
 Long wavelength UVA light (315–400 nm) has been effectively used for 
spatiotemporal control of compound release in vitro and in vivo in many fields including 
optogenetics
43
 and drug delivery,
16, 28
 while visible light (400–700 nm) has been used in clinics 
for photodynamic therapy (PDT).
42
 
 
Figure 1. ortho-Nitrobenzyl (ONB) photocleavable linkers used for light-controlled drug release 
in nanoparticle (NP) delivery systems. Two ONB linkers are illustrated, each terminated with an 
amine
5
 or alkyne
6
 functionality for NP tethering through amide or azide-alkyne click conjugation 
chemistry. 
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Linker chemistry developed for photocontrolled delivery is based largely on the concept of 
photocaging
44
 which enables the temporary inactivation of a molecule using a photocleavable 
group such that upon light irradiation, the active form of its caged molecule is irreversibly 
released (Figure 1). Many delivery systems have been successfully designed with this concept, in 
particular, utilizing long UVA-cleavable linkers consisting of ortho-nitrobenzyl (ONB)
4-6, 40, 41
 
and coumarin.
43, 45
 These linkers have been applied in the controlled activation or release of 
payloads including 5-fluorouracil (5-FU),
4
 methotrexate,
46
 doxorubicin,
5, 6, 40, 47, 48
 
ciprofloxacin,
11
 camptothecin,
49
 chlorambucil,
27
 folate,
41
 and Alexa fluor 488.
50
 However, 
despite their high utility for precise control and broad payload applicability, the accessibility to 
such ONB or coumarin linkers is often limited due to the synthetic challenges that are faced, as 
each linker requires an additional tethering functionality to be used as a chemical handle for NP 
crosslinking. For example, the use of ONB linkers such as ONB(NH2) as we previously reported
5
 
requires a total of seven divergent steps to get to the state where it is fully functionalized with an 
amine or alkyne unit for NP tethering through amide
5, 40
 or azide-alkyne click
6
 conjugation 
chemistry (Figure 1). 
With a practical perspective, to address these synthetic challenges in photocaging 
technologies, we have been interested in thioacetal ortho-nitrobenzaldehyde (TNB)
48
 as a new 
type of photolinker (Figure 2). As reported recently from our laboratories,
48
 each TNB linker (1 
and 2) has a photocaging group flanked by two identical arms. Because of their symmetry, each 
hydroxyl or carboxylic acid terminus can equally engage in either drug caging or NP tethering 
without incurring regioisomeric issues. Use of these TNB linkers offers synthetic convenience 
and large scale availability because of their synthesis from commercially available 6-
nitrovertraldehyde in one step. The thioacetal linkage that constitutes the core of TNB linkers 1 
 6 
and 2 displays rapid cleavage kinetics with quantum efficiencies (Φ = 0.19–0.2)48 as effective as 
comparable ONB linkers (Φ = 0.01–0.7).
44
 Both TNB and ONB share certain similarities in the 
initial step of the mechanism of cleavage which involves the generation of an aci-Nitro form in 
response to UV light (Figure 2).
48
 However, they show differences in subsequent fragmentation 
mechanisms and the distribution of release products as the TNB cleavage results in concomitant 
release of two species, proposed to be Dox(thiol) and Dox(thioester). 
 
Figure 2. A dual-arm linker strategy based on thioacetal ortho-nitrobenzaldehyde (TNB)
48
 and a 
proposed mechanism of drug release via a TNB cleavage triggered by long wavelength UVA 
(365 nm). 
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Our present study aims to evaluate the scope and validate the capability of TNB linkers in the 
targeted delivery of Dox, a clinical anticancer drug. It describes the methods involved in the 
synthesis of TNB-caged Dox conjugates and discusses the strategies developed for integrating 
these TNB-caged molecules into two FAR-targeting NP modules. The first NP module is based 
on a fifth generation (G5) poly(amidoamine) (PAMAM) dendrimer,
3
 G5(FA)(Dox), in which FA 
and TNB-Dox are conjugated to the terminal amines of the dendrimer branches.  The second NP, 
UCN-PPIX@(Dox)(G5FA), is based on a core/shell upconversion nanocrystal (UCN)
51
 platform 
in which a UCN-PPIX (protoporphyrin IX)
36
 core is covalently coated with both a targeting 
G5(FA)6 dendrimer and a TNB-caged Dox drug on its shell surface as two separate entities. This 
UCN-PPIX nanostructure was employed because its UCN core offers the unique ability to 
upconvert near IR (NIR) radiation into UV–vis emission,36 which serves as an internal light 
source for imaging and inducing the cleavage of the TNB linker. In addition, the presence of the 
PPIX layer coupled as a photosensitizer on the UCN surface was shown to be effective for 
producing reactive oxygen species (ROS) which led to photo-modulated cytotoxicity.
36
 
Results and Discussion 
TNB-caged Doxorubicin. 1 TNB(OH) was synthesized from 6-nitroveratraldehyde by its 
reaction with 2-mercaptoethanol in a one-pot synthesis catalyzed by BF3·Et2O as reported 
previously (Scheme 1).
48
 Each hydroxyl group in 1 was then activated by treatment with 4-
nitrophenyl (4-NP) chloroformate to an amine-reactive form, bis(4-nitrophenyl) carbonate 3. 
Because of their symmetry, each arm in 3 is equally able to engage in a conjugation reaction, 
allowing attachment of the TNB to two different molecules in reactions performed in sequence, 
such as first conjugation of one arm with a drug molecule and then conjugation of the other arm 
to a nanocarrier. Thus, 3 reacted with Dox to produce 4 through a carbamate linkage while 
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leaving the other carbonate intact to be used later for tethering to a UCN-PPIX carrier which 
presents amines on the surface. As an alternative approach, 3 was first conjugated with mono N-
Boc protected ethylenediamine and subsequently with Dox, yielding 5. Its N-Boc group could be 
deprotected to produce a free primary amine for its amide conjugation with a carboxylic acid-
terminated PAMAM dendrimer. 
The structural identity and homogeneity (≥95%) of each of the TNB-caged compounds 3–5 
were fully established by 
1
H NMR spectroscopy and ultraperformance liquid chromatography 
(UPLC) analysis (Figure S1, Supporting Information). Some of these compounds were further 
characterized by UV–vis spectrometry (5: max = 498 nm (Dox),  = 7882.7 M
−1 
× cm
−1
); 355 nm 
(TNB),  = 4575.4 M−1 × cm−1) and by high resolution mass spectral data which confirmed an 
agreement between the calculated and experimental values (m/z calcd for C48H49N3NaO22S2 [4 + 
Na]
+
 1106.2141; found 1106.2134; calcd for C49H60N4NaO21S2 [5 + Na]
+
 1127.3089, found 
1127.3072). 
Scheme 1. Synthesis of a thioacetal ortho-nitrobenzaldehyde (TNB) photolinker and its 
doxorubicin conjugates
a 
 9 
 
a
Reagents and conditions: i) 2-Mercaptoethanol, BF3·Et2O, acetic acid, 0
o
C; ii) 4-Nitrophenyl 
chloroformate, i-Pr2NEt, CH2Cl2; iii) Doxorubicin-HCl, Et3N, DMF; iv) N-Boc ethylenediamine, 
Et3N, CH2Cl2. 
Scheme 2. Synthesis of 9 G5(FA)n=5.4(Dox)m=5.1, a G5 PAMAM dendrimer conjugated with 
folate (FA) and TNB-caged Dox
a 
 10 
 
a
Reagents and conditions: i) CF3CO2H, CH2Cl2, room temp; ii) Glutaric anhydride (220 mol 
equiv), Et3N, MeOH, room temp; iii) N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (EDC), N-hydroxysuccinimide (NHS), DMF, 36 h, room temp; iv) 6 (10 mol 
equiv), 7 (20 mol equiv), NEt3, room temp. 
TNB(Dox)-Conjugated PAMAM Dendrimer. In order to explore the applicability of TNB 
linker 1 in photocontrolled drug delivery, we selected a fifth generation (G5) poly(amidoamine) 
(PAMAM) dendrimer G5(NH2)n (n = theoretical number of peripheral amine branches = 128, 
diameter = 5.4 nm)
3
 as a nanoscale drug carrier. This class of PAMAM dendrimers displays 
excellent structural and functional features ideal for multivalent ligand presentation and drug 
delivery due to their large number of pre-organized peripheral branches, flexible shape, and 
hydrophobic internal cavities.
3
 As previously used for amide drug conjugation,
5, 11
 a glutaric acid 
(GA)-terminated dendrimer 8 (Mr = 40,200 gmol
−1
; polydispersity index (PDI) = Mw/Mn 
~1.046)
5
 which was prepared by treatment of G5(NH2)n =114 with excess glutaric anhydride, 
served as a platform for conjugating TNB(Dox). This dendrimer was preactivated at its 
 11 
peripheral carboxylic acids by treatment with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
(EDC)/N-hydroxysuccinimide (NHS), and was subsequently incubated with a mixture of 6 and 7, 
a folate (FA) ligand (KD = 5.9 × 10
−6
 M; monovalent FA to folate binding protein
40
) to produce 
9. 
The dendrimer conjugate was purified through multiple cycles of exhaustive dialysis in a 
membrane tubing (MWCO 10 kDa), and its identity was characterized by standard methods 
including UV–vis spectrometry for the respective chromophores (max = 283 & 355 for FA & 
TNB; 497 nm for Dox), matrix assisted laser desorption ionization time-of-flight (MALDI–TOF) 
mass spectrometry (Mr = 48,000 gmol
−1
), and UPLC for homogeneity (>95% polymer purity) 
(Figure S1, Supporting Information). The ligand (n) or drug (m) valencies indicated for 9 
G5(FA)n(Dox)m refers to the number of FA or TNB(Dox) molecules attached to each dendrimer 
nanoparticle, determined on an average basis by a H NMR integration method in combination 
with UV–vis analysis (Beer-Lambert Law) as reported previously:40 FA (nmean = 5.4, 
1
H NMR); 
TNB(Dox) (mmean = 5.1, UV–vis) (Table S1, Supporting Information). 
Modular Integration of TNB(Dox) with UCN-PPIX. Among various light sources, long 
wavelength UVA is highly effective as a trigger for controlled release of photocaged compounds, 
though it faces certain limitations which are mostly related to its relatively poor tissue 
penetration.
52
 However, many of these issues are addressable by using photoluminescent UCNs 
as the nanoplatform.
51
 UCNs are excited by NIR (980, 800 nm) light which displays deeper 
tissue penetration.
52
 Upon excitation by NIR, UCNs have an intrinsic mechanism by which they 
are able to upconvert this excitation energy to emission at shorter visible and UV bands. 
 12 
 
Figure 3. (A) Modular assembly and (B-F) physical and spectroscopic characterization of 
upconversion nanocrystal (UCN)s 10–12. Transmission electron microscopy (TEM) images of 
UCN (-NaYF4: 20% Yb, 2% Er) (B), 10 (C), and 12 (D). (E) Upconversion luminescence 
spectra of UCNs acquired by excitation at 980 nm. Inset: A photograph showing emitted light. 
(F) Overlaid UV–vis absorption spectra of UCNs 10–12 (1.0 mg/mL in MeOH). reagents and 
conditions: i) 4, MeOH, room temp; ii) G5(FA)6, EDC, NHS, DMF, 36 h, room temp. UCN = 
NaYF4: 20% Yb, 2% Er. Abbreviations: UCN = upconversion nanocrystal; PPIX = 
protoporphyrin IX 
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As described in our report
36
, 10 was prepared from UCN (NaYF4: 20% Yb, 2% Er)
40
 by 
surface coating with a thin siloxane polymer layer made of both protoporphyrin IX (PPIX)-
Si(OEt)3 and (3-aminopropyl)triethoxysilane (APTES) (Figure 3). The purpose of including this 
shell modification under a co-silanization condition was to incorporate PPIX as a photosensitizer 
to generate reactive oxygen species (ROS) as well to present an amine-coated surface for 
functionalization with TNB(Dox). 
Surface amines in 10 were then used for conjugation with Dox through a TNB linker and 
with the G5(FA)6 dendrimer which is introduced to serve as a FAR-targeting multivalent ligand 
(KD = 5.9 × 10
−9
 M to folate binding protein
40
). This modular assembly was performed in a two-
step reaction sequence, first by crosslinking with amine-reactive 4, which resulted in 11 through 
a chemically stable carbamate bond. Colorimetric analysis of the reaction mixture by UV–vis 
spectrometry (max = 400 nm) suggested 44.6% yield of TNB(Dox) conjugation which is 
equivalent to 4.3% (w/w). In a second step, G5(FA)6 was conjugated to 11 by an EDC-based 
amide coupling method, which resulted in 12. The efficiency of G5(FA)6 conjugation was 
estimated as 12.3% by UV–vis analysis (max = 275 nm) of the reaction supernatant, which is 
equivalent to 3.1 % (w/w). These surface modifications of UCN-PPIX are evident in the overlaid 
UV–vis spectra of UCNs 10–12 in Figure 3F which show spectral features attributable to 
TNB(Dox) (max = 445–512 nm) and G5(FA)6 (max = 220, 285 nm). 
Physical properties of UCNs 10–12 were characterized by transmission electron microscopy 
(TEM) to determine their shape and size distributions (Figure 3B–3D). First, the core UCNs (-
NaYF4: 20% Yb, 2% Er) were composed of hexagonal nanocrystals with an average diameter of 
~42 nm with a narrow distribution of size (range = 39–44). Their hexagonal lattice structure was 
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previously confirmed by the analysis of selected area electron diffraction (SAED) patterns 
(inset).
40
 TEM images of core-shell nanostructured UCNs 11–12, each derived from 10, show 
similarities with 10 in their shape and size distributions. However, they show some minor, yet 
notable differences as compared to the parent UCN in their outer layers which appear to be less 
dense, but thicker than that of 10, which is supportive of surface modification with dendrimer 
and Dox molecules. 
The photophysical properties displayed by the core UCN (-NaYF4: 20% Yb, 2% Er) were 
investigated by NIR irradiation at 980 nm in a continuous wave (CW) mode (1 W; output = ∼5 × 
10
18 
photons s
−1
). This UCN shows a luminescent property composed of three UV–vis emission 
peaks (Figure 3E), each assigned to Er
3+ 
upconversion transition including a weak UV band (max 
= 380, 410 nm; 
4
G11/2/
2
H9/2→ 
4
I15/2), and two strong bands at green (max = 550 nm; 
4
S3/2 → 
4
I15/2) and red (max = 651 nm; 
4
F9/2 → 
4
I15/2) wavelengths.
53
 
Photolysis of TNB(Dox). We next investigated the efficiency of the photolytic cleavage of 5 
(20% MeOH/H2O) by long wavelength UVA (Figure 4). Like the photolinker 1 itself, which 
showed a rapid decrease in absorbance at its max at 346 nm (ε = 4,292 M
−1
 cm
−1
),
48
 the UV–vis 
spectral traces of this TNB-caged Dox showed a similar decrease in absorbance at max 355 nm 
with no apparent change in the Dox absorbance (max 497 nm). Kinetic analysis of TNB 
absorption traces suggests that its photolysis occurs rapidly with a first order rate constant (kobsd 
= 0.181 min
−1
, Figure 4B). 
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Figure 4. Photolysis of TNB-caged doxorubicin (Dox) in 5 in aqueous methanol by UVA (365 
nm). (A, B) Overlaid UV–vis spectral traces and changes in absorbance (Ab350) as a function of 
light exposure time: [5]t=0 = 4.53 × 10
-5
 M. (C, D) UPLC traces and the kinetic analysis of Dox 
release: [5]t=0 = 9.05 × 10
-5
 M. 
UPLC analysis was performed to identify the photolytic products of 5 (Figure 4C). Its traces 
showed the appearance of two major peaks, each appearing at a shorter retention time than its 
parent 5. This result is consistent with the anticipated mechanism of concomitant release of two 
Dox-terminated species, proposed to be Dox(thiol) and Dox(thioester). An LC–MS analysis 
performed after 5 min of irradiation showed a peak at m/z 686.2486 which points to the release 
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of Dox(thiol) (calcd for C30H33KNO13S [Dox(thiol) + K]
+
, found 686.1310). The decay of 5 
occurred following an exponential curve, and its area under curve (AUC) analysis led to an 
observed rate constant kobsd of 0.221 min
−1 
which is close to the value (0.118 min
−1
) calculated 
from its UV–vis analysis above. The quantum yield of 5 in TNB cleavage (Φcleavage = 0.22) 
which was determined relative to ferrioxalate actinometry (Ф = 1.26), indicates that its cleavage 
occurs as efficiently as its parent linker 1 (Φcleavage = 0.19)
48
 apparently without any effect from 
Dox conjugation. 
 
 
Figure 5. Photolysis of 9 G5(FA)5.4(Dox)5.1 conjugate. (A) Overlaid UV–vis spectra and (B) 
UPLC traces of 9 (3.52 × 10
-6
 M in PBS, pH 7.4) after exposure to UVA (365 nm). Relative 
absorbance (Ab) values at each detection wavelength (A, right) are calculated by normalization 
to an initial value (Abt=0) measured prior to irradiation. Abbreviation: tr = retention time  
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Photolysis of TNB(Dox)-caged Dendrimer. Kinetic studies of Dox release by UVA light 
were continued with the dendrimer conjugate 9 by monitoring its progress with UV–vis 
spectrometry and UPLC (Figure 5). Changes in the absorbance corresponding to Dox at 490 nm 
appeared to be insignificant in the spectral traces, however, significant changes in absorbance 
were observed at shorter wavelengths of 283 nm and 350 nm, which are associated with the 
absorbance of FA and TNB, respectively. The absorbance at 350 nm decreased rapidly, reaching 
a minimum around 5 min as seen with 5 (Figure 4A), however it gradually increased (Figure 5A, 
right). Such absorption features are partly consistent with those observed in the photolysis of a 
comparable ONB(Dox)-conjugated dendrimer under a similar condition.
5
 These might be 
attributable to the subsequent oxidation of a nitrosobenzoyl group tethered at the dendrimer to its 
corresponding nitrobenzoyl group which could restore a higher molar absorptivity. In addition, 
complexation of released Dox species in the hydrophobic environment surrounded with dendritic 
branches may also contribute to this growth. 
UPLC analysis of the photolysed solutions of 9 showed an irradiation time-dependent course 
of peak shifts as shown by overlaid UPLC traces (Figure 5B). Prior to irradiation, 9 appears as a 
broad peak (retention time tr = 8.4 min), which could be attributable to the broad distributions in 
valencies of FA (n = 1–11; mean = 5.4; median  = 6) and Dox (m = 1–10; mean = 5.1; median = 
5) as predicted by a Poisson simulation
54
 (Figure S2, Supporting Information). In response to 
increased exposure times, this broad peak shifted towards a shorter tr, rapidly reaching a plateau 
(Figure 5B, right). However, peaks for released Dox species were not resolvable from the 
broader dendrimer peaks, and they might be entirely buried within the dendrimer peaks. The 
elution profiles of 9 were observed similarly with the UPLC analysis of the ONB(Dox)-
 18 
conjugated dendrimer G5(FA)6(Dox)6.9, in which the shorter tr values were attributable to smaller 
NP sizes obtained as a result of Dox release.
40
 
In summary, the photolysis results of 5 and its dendrimer conjugate 9 suggest certain 
similarities in the photochemical properties between the TNB and ONB linker. First, Dox release 
occurs rapidly in both TNB(Dox) and ONB(Dox),
40
 each achieving ≥80% linker cleavage after 
only 4 min of UVA exposure. Second, TNB cleavage occurs more slowly in its dendrimer 
conjugate 9 than its unconjugated form 5, as was the case for ONB(Dox) and its dendrimer 
conjugate in a corresponding study.
40
 This lowered efficiency is proposed to be caused by the FA 
co-attached to the dendrimer as its pteridine chromophore has a strong molar absorptivity in the 
UV region (max = 354 nm;  = 62,800 M
−1
cm
−1
) and can competitively absorb a fraction of the 
UV excitation. 
 
Figure 6. Light control of the cytotoxicity of 5 TNB(Dox)(NHBoc) (A), 9 G5(FA)5.4(Dox)5.1 (B) 
and comparison of their toxicities on a Dox basis (C). Cellular viability was measured in FAR(+) 
KB tumor cells in vitro with or without exposure to UVA (365 nm). Error bars invisible in Dox 
and +UV data points are buried within the symbols. Mean ± SD (N = 2). 
Light-controlled Cytotoxicity of TNB(Dox) and its Dendrimer Conjugate. We next 
investigated the ability of light to modulate the cytotoxicity of 5 in FAR overexpressing KB 
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cells, an epithelial carcinoma cell line. Cells were initially incubated with the test compounds for 
a total of 30 min for both +UVA and –UVA samples. The –UVA cells were then incubated at 37 
ºC for an additional 24 h.  For +UVA cells, treated cells were exposed to UVA for 10 min prior 
to the same incubation at 37 ºC for 24 h. The media was then replaced with fresh media after the 
incubation, and the cells were grown for 4 more days prior to measuring the cellular viability by 
an XTT assay. As summarized in Figure 6A, 5 displayed minimal cytotoxicity without light 
exposure, even at high concentrations (≥80% viability at up to 25M), as anticipated for the 
caged drug molecule. In contrast, unmodified Dox displayed potent cytotoxicity at low 
concentrations (≤10% viability at 1 M). After 10 min of exposure to UVA, the viability of cells 
treated with 5 reduced in a dose-dependent manner to ≤30% at concentrations ≥6 M (Figure 
6B), indicative of light-induced cytotoxicity. As a control, untreated KB cells were exposed to 
UVA light for the same period, and no effect on cell viability was observed, which is consistent 
with earlier results.
40, 48
 The maximal level of cytotoxicity by 5 is, however, lower than that of 
free Dox. It might be associated with the release of Dox(thiol) and Dox(thioester) (Figure 2), and 
their relatively slow conversion to free Dox in the cells.
48
 
Conjugate 9 was similarly investigated for its cytotoxicity in FAR(+) KB cells. As seen with 
5, it lacked intrinsic cytotoxicity but became cytotoxic in a dose-dependent manner to the tumor 
cells when triggered by UVA exposure (Figure 6B). The FAR-targeted dendrimer conjugate 
showed a greater extent of cytotoxicity (<10% in viability) at the highest dose compared to the 
untargeted conjugate 5. We attribute this greater extent of cytotoxicity by 9, in part, to its 
multivalent ligand design that confers tight, FAR-specific binding to cellular surface receptors 
(KD = 1.7 × 10
−8
 M; multivalent FA 9 to folate binding protein).
5, 40
 Furthermore, FAR-mediated 
endocytosis
55
 of the surface receptor bound dendrimer may lead to more efficient intracellular 
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uptake, further enhancing Dox delivery.
5, 40
 Dendrimer facilitated uptake of Dox, was supported 
by wash-out experiments, in which KB cells were treated with 5 or 9 for 30 min followed by 
extensive washing of the cells prior to UVA exposure. While 5 showed minimal toxicity after 
washing, 9 still showed significant light-triggered cytotoxicity, supporting the intracellular 
uptake of the dendrimer prior to the wash step (data not shown). When compared on a per Dox-
basis, however, the light-induced cytotoxicity of dendrimer conjugate 9 appeared slightly 
reduced compared to 5 (Figure 6C), which is likely attributable to the slower rate of TNB 
cleavage in 9 (Figure 5) and the slow kinetics of Dox(thiol) and Dox(thioester) conversion to 
Dox (Figure 2). 
Cellular FAR Targeting and Binding of UCN Conjugates In Vitro. In our previous 
report,
40
 we were able to detect the UCN conjugate bound and internalized in KB cells by 
confocal microscopy using the NIR luminescence (ex = 980 nm; ex = 550, 650 nm) of the 
nanoparticle. The NIR luminescent properties of the UCN core allow for imaging without the 
need for labelling with an exogenous fluorophore. We applied the same technique to evaluate the 
tumor targeting capability of current UCN conjugates in FAR (+) KB cells. Figure 7 (A, B) 
shows images of KB cells treated with 11 or 12, each at 500 g/mL for 2 h at 37 °C. Cellular 
binding and uptake were dramatically increased for 12, the FAR-targeted UCN coated with 
G5(FA)6, compared to 11, which lacks the targeting dendrimer. A similar set of imaging 
experiments were performed in FAR(−) B16 cells in vitro (Figure 7C, 7D), which did not show 
as much binding for either 11 or 12 as for the KB cells, however there was no significant 
difference found between the cells treated with 11 or 12. In fact, 12 appeared to bind slightly less 
to the FAR(−) cells than 11. These results are supportive of the FAR specificity of 12 in KB 
cells. 
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Figure 7. Cellular binding and flow cytometric analysis of UCN conjugates in vitro. 
Fluorescence confocal microscopy images of FAR(+) KB cells (A, B) or FAR(−) B16 cells (C, 
D) treated with 11 UCN-PPIX@(Dox) or 12 UCN-PPIX@(Dox)(G5FA), each at 500 g/mL, 
imaged by NIR luminescence (λex = 980 nm; λem = 550 nm, 650 nm). Color codes: DAPI (blue: 
nuclei), UCN (red). (E, F) Flow cytometry analysis of FAR(+) KB cells incubated with Cy5-
labeled 11 and 12 for 1 h at 37 ºC. Cellular binding and/or uptake of the conjugates was 
determined by the cell associated mean fluorescence intensity (MFI) in the Cy5 channel and 
expressed as a function of the UCN dose (E). Competitive ligand displacement of KB cells by 
co-incubation of Cy5-labeled 11 or 12 (each at 0.1 mg/mL) with increasing concentrations of 
free folate (F). Cell-associated fluorescence was measured in a Cy5 channel. Mean (±SD). 
 
This difference observed by confocal microscopy was further evaluated by flow cytometric 
analysis performed using Cy5-labeled 11 or 12 in KB cells ([11 or 12] = 5, 10, 100 g/mL; 
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Figure 7E). Comparison of the mean fluorescence intensity (MFI) of the population of bound 
cells demonstrates that 12 exhibits dose-dependent binding, yielding higher MFIs than the non-
targeted UCN 11 at the lower concentrations. For example, at the 10 g/mL concentration, UCN 
12 had a nearly 7-fold higher MFI than 11. While 11 showed minimal or no binding at the lower 
concentrations, at the highest dose (100 g/mL) a significant amount of binding was observed. 
This is likely due to nonspecific binding attributable to electrostatic interactions between the 
positively charged 11 and the cell membrane surface.
56
 However, the amount of binding of 11 
even at this highest dose was still lower than that of the targeted UCN 12. Furthermore, the 
slightly greater nonspecific binding observed by flow for 11 compared to the confocal analysis 
may also be due to the presence of the Cy5 fluorophore on the UCNs used for flow analysis 
which was not present on the UCNs in the confocal studies. Binding of 12 however, shows FAR 
specificity as evidenced by the ability of free FA to compete for its binding to FAR(+) KB cells 
(Figure 7F). In the ligand displacement assay, the KB cells were co-incubated with excess FA 
(KD = 5.9 × 10
−6
 M) 
40
 added at increasing concentrations prior to addition of the UCNs. The 
percentage of cells containing bound UCN decreased for UCN 12 by ~10% at 1 mM FA, but did 
not change for UCN 11 even at the high FA concentration. However, the lack of complete 
displacement by FA is indicative of the tight adsorption of multivalent G5(FA)6 to the cell 
surface receptors which displays high binding avidity (KD = 5.9 × 10
−9
 M).
40
 These results 
demonstrate the ability of the G5(FA)6 dendrimer to impart FAR targeting to the UCN complex, 
and show that attachment to the UCN did not interfere with the binding of G5(FA)6 to surface 
FAR. 
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Figure 8. Controlled cytotoxicity of 10 UCN-PPIX, 11 UCN-PPIX@(Dox), and 12 UCN-
PPIX@(Dox)(G5FA) in FAR(+) KB cells in vitro. Cell viability of UCN treated cells was 
measured without light exposure (A), or after exposure to UVA (365 nm, 10 min) (B) or NIR 
(980 nm, 1 h) [UCN] = 0.75 mg/mL) (C). Mean ± SD (N = 2–4). 
 
Light-controlled Cytotoxicity of UCN Conjugates. To characterize the efficiency of UCN 
conjugates 10–12 in inducing cytotoxicity in a light-modulated manner, cytotoxicity assays were 
performed in KB cells (Figure 8). This cytotoxicity assay was performed similarly to our prior 
study,
40
 in which the cells were incubated at 37 °C for 30 min with each UCN conjugate at 
variable concentrations ([UCN] = 0.03–0.75 mg/mL) to allow cellular binding and uptake, and 
exposed to either UVA (365 nm) for 10 min or NIR (980 nm) for 1 h. After light exposure, the 
cells were treated as described for Figure 6 prior to performing an XTT assay for measurement 
of cell viability. 
As shown in Figure 8A, incubation with 10–12 without light exposure led to normal growth 
and viability, indicating a lack of intrinsic cytotoxicity by each UCN conjugate except 10 which 
showed a low level of cytotoxicity at its highest dose (0.75 mg/mL). However, subsequent UVA 
exposure led to a large decrease (10, 11) or dose-dependent decrease (12) in cell viability. First, 
10 which lacks Dox displays very potent cytotoxicity upon UVA exposure. This potent 
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cytotoxicity is consistent with our previous results,
36
 and is attributable to the mechanism of the 
photodynamic activation of PPIX molecules in the shell layer (max = 408 nm, Figure 3G), by 
which cytotoxic ROS could be generated. Second, 12, the FAR-targeted conjugate which is more 
effective in cellular binding than 11 in FAR(+) KB cells (Figure 7), showed otherwise a slightly 
reduced cytotoxicity. We believe this lower activity might be attributable partly to slower drug 
release due to the absorbance of UVA radiation by the G5(FA)6 on the surface and/or the delayed 
metabolic conversion of released Dox species as suggested for 9 (Figure 6). In summary, each 
UCN conjugate which carries the PPIX photosensitizer alone or in combination with TNB-caged 
Dox showed highly effective UV light-dependent cytotoxicity in tumor cells. 
Use of NIR (980 nm) was then studied to control the cytotoxicity of UCN conjugates 10–12. 
FAR(+) KB cells were incubated with each conjugate at 750 g/mL, a high dose selected to 
achieve a sufficient level of cell binding for comparison (Figure 7E), and the treated cells were 
exposed to NIR radiation (980 nm) for 1 h. Figure 8C compares the cell viability in the presence 
of the three conjugates measured with/without NIR exposure. Under the no NIR condition, the 
two non-targeted conjugates 10 and 11, showed some cytotoxicity, each causing ~15% and 
~10% reduction in cellular viability, respectively, compared to 12 which lacked such intrinsic 
toxicity. Exposure of the UCN treated cells to NIR had a significant impact on the cell viability, 
but NIR exposure alone had no impact on cells in the absence of UCN (Figure 8C). Each of the 
UCN conjugates was equally effective and almost indistinguishable in inducing potent 
cytotoxicity, resulting in less than 5% cell survival. This result might be attributable to the 
additivity of at least three effects, each contributed by the intrinsic toxicity of UCN-PPIX, the 
potent ROS mechanism of PDT,
36
 and the release of Dox species. However, it is notable that 12 
appears to be the most desirable delivery system due to its lack of intrinsic toxicity, FAR-specific 
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cell binding, and NIR-inducible cytotoxicity. While not as critical in a closed in vitro system, 
where free drug is maintained in the media upon release, the large enhancement in UCN binding 
and targeting specificity facilitated by the attached G5(FA)6 dendrimer may be more important in 
vivo where circulation of interstitial fluid makes concentrated and localized delivery critical for 
maximal impact and minimal systemic toxicity. 
In summary, this study describes the kinetics and effects of Dox release from these TNB-
caged Dox conjugates with the light trigger in solution and FAR-overexpressing (+) KB tumor 
cells in vitro. The rapid release kinetics was observed upon UVA light stimulation in solution, 
and it was consistent with their observed ability to potently induce cytotoxicity in the tumor cells 
as modulated by exogenous light triggers. Furthermore, the UCN core/shell nanoconjugates were 
investigated for FAR-specific cellular uptake and NIR imaging by confocal microscopy without 
the need for an added fluorophore due to the intrinsic luminescence properties of the UCN core. 
The findings of this current study present significant insights on the new TNB-based conjugate 
system by presenting several sets of data supportive of its synthetic practicality, conjugation 
modularity demonstrated with two representative NPs, and its applicability for light-controlled 
drug cytotoxicity. 
Conclusion 
First, we have demonstrated the design of a dual-arm TNB linker and its utility for light-
controlled Dox delivery in two representative nanoscale platforms. This TNB strategy has 
significant potential for enhancing our capability to advance the field of controlled delivery 
technologies by addressing the synthetic challenges and lengthy procedures often associated with 
drug-NP conjugation.
5, 6
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 Currently, several classes of photolinkers
26, 44
 have been developed 
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for light-controlled delivery, each based on the scaffold of ONB,
4-6, 27
 coumarin,
43
 carbazole,
57
 
and cyanine.
58
 Compared to these photoactive linkers, TNB
48
 is validated as an important tool in 
this study due to its unique benefits such as its symmetric structure, synthetic convenience, and 
large scale accessibility. 
Second, this study investigated the specific capability and efficiency of the TNB-Dox 
conjugation method by its application to known drug delivery systems including dendrimer 
conjugates
2, 5, 17
 and modularly integrated UCNs.
36, 40
 Integration of multiple functionally distinct 
components into a single nanostructure could be challenging in this field, but this study 
illustrates an improved process for NP-drug conjugation using a TNB-caged Dox payload in two 
distinct nanostructures represented by dendrimer polymers or photonic UCNs. 
Third, each of the two FAR-targeted NPs reported here offers the ability to actively control 
drug delivery using either UVA or NIR which triggers drug release indirectly by UVA emitted 
from the UCN core. Given the recent advances in optical fiber technologies, each delivery 
system suggests potential for enabling spatially and temporally restricted drug release to various 
FAR(+) tumor cells localized in the epidermis or vascular endothelia using a UVA or NIR laser 
which allow for much deeper tissue penetration beyond the epidermal layers.
52
 Future efforts will 
be directed towards advancing the scope of the thioacetal strategy by expanding its use to other 
classes of photocages such as coumarin for wavelength-selective release. 
Experimental Section 
Materials, general synthetic methods and analytical methods (
1
H NMR, UV–vis 
spectrometry, mass spectrometry, UPLC, TEM) are detailed in Supporting Information. 
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1 TNB(OH). The detailed synthesis of 1 was reported in our earlier publication.
48
 In short, 
this thioacetal was prepared in one step from 4,5-dimethoxy-6-nitrobenzaldehyde (6-
nitroveratraldehyde) by reacting with 2-mercaptoethanol (2 × 2.5 mol equiv) in dichloromethane 
containing a mixture of acetic acid and BF3∙Et2O as a catalyst. MS (ESI) m/z (relative intensity, 
%): calcd 372.06 for C13H19NNaO6S2 [M + Na]
+
; found 372.0 (10), 212.0 (100). 
1
H NMR (500 
MHz, CD3OD):  7.55 (s, 1H, Ha), 7.50 (s, 1H, Hb), 6.09 (s, 1H, Hc), 3.95 (s, 3H, Hd), 3.90 (s, 
3H, Hd’), 3.68–3.66 (t, J = 7 Hz, 4H, He), 2.83–2.78 (m, 2H, Hf), 2.70–2.65 (m, 2H, Hf) ppm. 
UV–vis (10% aqueous methanol): max = 346 ( = 4,292 M
-1
cm
-1
), 248 ( = 11,560 M-1cm-1) nm. 
3 TNB(4-NP) (Scheme 1). To a stirred solution of 1 (200 mg, 0.573 mmol) and N,N-
diisopropylethylamine (0.43 mL, 2.40 mmol) in chloroform (4 mL) was added a solution of 4-
nitrophenyl chloroformate (242 mg, 1.20 mmol) in anhydrous tetrahydrofuran (2 mL). The 
mixture was stirred at room temp overnight, and followed by the addition of a second portion of 
4-nitrophenyl chloroformate (242 mg, 1.20 mmol) and 4-dimethylaminopyridine (147 mg, 1.20 
mmol). After stirred for an additional period of 3 h, the mixture was concentrated in vacuo, and 
the residue was dissolved in 10 mL of ethyl acetate. The organic solution was washed with a cold 
saturated sodium bicarbonate solution (5 mL) and water (5 mL), and then dried over anhydrous 
sodium sulfate. After concentration in vacuo, the crude product was purified by flash column 
chromatography (silica gel) by eluting with ethyl acetate/hexane (1:5 to 1:2). The desired product 
was obtained as a pale yellow syrup (232 mg, 60%). TLC (1:1 ethyl acetate/hexane): Rf = 0.63. 
MS (ESI) m/z (relative intensity, %): calcd 702.07 for C27H25N3NaO14S2 [M + Na]
+
; found 702.0 
(6.9), 437 (100). 
1
H NMR (500 MHz, CDCl3): 8.28–8.26 (d, J = 10 Hz, 4H, 4-NP), 7.53 (s, 1H, 
Ha), 7.45 (s, 1H, Hb), 7.39–7.37 (d, J = 10 Hz, 4H, 4-NP), 6.29 (s, 1H, Hc), 4.51–4.43 (m, 4H, 
He), 4.02 & 3.94 (two s, 3H, Hd, & Hd’), 3.11–3.06 (m, 2H, Hf), 2.96–2.90 (m, 2H, Hf) ppm. 
 28 
4 TNB(Dox)(4-NP) (Scheme 1). To a solution of doxorubicin hydrochloride (26 mg, 0.044 
mmol) in anhydrous dimethylformaldehyde (2 mL) was added N,N-diisopropylethylamine (0.023 
mL, 0.13 mmol) and TNB(4-NP) (75 mg, 0.11 mmol) in dimethylformaldehyde (1 mL). The 
mixture was stirred at room temp for 5 h, and dimethylformaldehyde was removed under 
reduced pressure. The crude product was purified by flash column chromatography by eluting 
with 3% methanol/chloroform. The desired product was obtained as red solid (45 mg, 93%). 
TLC (3% methanol/chloroform): Rf = 0.38. MS (ESI) m/z (relative intensity, %): calcd 1106.21 
for C48H49N3NaO22S2 [M + Na]
+
; found 1106.0 (100). HRMS (ESI): calcd 1106.2141 for [M + 
Na]
+
, found 1106.2134. 
1
H NMR (500 MHz, CDCl3): 8.28–8.26 (m, 2H, 4-NP), 8.05–8.03 (d, J = 
10 Hz, 1H, Dox-2), 7.81–7.77 (t, J = 10 Hz, 1H, Dox-3), 7.46 (s, 1H, Ha), 7.41–7.37 (m, 4H, Hb), 
Dox-1 and 4-NP), 6.24 (s, 1H, Hc), 5.52–5.48 (m, 1H, Dox-1´, 4.76 (s, 2H, Dox-14), 4.52–4.44 
(m, 2H, He), 4.32–4.10 (m, 4H, Dox-4´, Dox-5´, He), 4.08 (s, 3H, Dox-OCH3), 3.99 & 3.93 (two 
s, 6H, Hd & Hd’), 3.84–3.82 (m,1H, Dox-3´), 3.68–3.66 (d, J = 10, 1H, Dox-7), 3.32–3.26 (m, 
1H, Dox-10), 3.06–3.02 (m, 1H, Dox-10), 3.10–2.60 (m, 4H, Hf), 2.38–2.33 (m, 1H, Dox-8), 
2.18–2.12 (m, 1H, Dox-8), 1.88–1.72 (m, 2H, Dox-2´), 1.31–1.25 (m, 3H, Dox-6´) ppm. 13C 
NMR (100 MHz, CDCl3): 213.86, 187.08, 186.69, 161.06, 156.21, 155.01, 153.63, 152.37, 
148.53, 145.48, 140.23, 135.50, 133.63, 130.03, 125.31, 121.82, 120.88, 119.85, 111.57, 107.65, 
100.76, 69.57, 69.24, 67.55, 67.33, 65.54, 64.90, 56.68, 47.50, 47.11, 35.62, 34.00, 31.92, 31.23, 
29.94, 16.92 ppm. 
5 TNB(Dox)(NHBoc) (Scheme 1). To a cold solution of 3 (56 mg, 5.17 mol) in 1.0 mL of 
anhydrous tetrahydrofuran was added a solution of N-Boc ethylenediamine (13.2 mg) and 
triethylamine (0.0345 mL) dissolved in tetrahydrofuran (0.5 mL) in an ice bath (~5 °C). The 
mixture was stirred at 5 °C for 1 h, and at room temp for 6 h. After the reaction, the mixture was 
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diluted with ethyl acetate (6 mL), and washed multiple times with a brine solution, 0.5 M HCl (5 
mL), and a brine solution. After drying over sodium sulfate, the solution was concentrated in 
vacuo, and the crude product was purified by silica column chromatography by eluting with 
ethyl acetate/hexane (1:2 to 1:1). TNB(4-NP)(NHBoc) was obtained as a pale yellow syrup (24 
mg, 41%). TLC (1:1 ethyl acetate/hexane): Rf = 0.28. 
1
H NMR (500 MHz, CDCl3): 8.29–8.27 (d, 
J = 10 Hz, 2H, 4-NP), 7.49 (s, 1H, Ha), 7.43 (s, 1H, Hb), 7.41–7.39 (d, J = 10 Hz, 2H, 4-NP), 6.27 
(s, 1H, Hc), 4.50–4.47 (t, J = 7.5 Hz, 2H, He’), 4.28–4.22 (m, 2H, He), 4.01 & 3.94 (two s, 3H, Hd & 
Hd’), 3.29–3.24 (m, 4H, 2CH2N), 3.14–3.08 (m, 1H, Hf’), 2.97–2.85 (m, 2H, Hf), 2.72–2.68 (m, 1H, 
Hf’) ppm. 
To a solution of TNB(4-NP)(NHBoc) (24 mg, 0.034 mmol) in dimethylformaldehyde (1.0 
mL) was added doxorubicin hydrochloride (21 mg, 0.036 mmol) and triethylamine (0.011 mL, 
0.082 mmol). The mixture was stirred at room temp in the dark overnight, and concentrated to 
0.5 mL. This solution was diluted with ethyl acetate (10 mL), and washed multiple times with 
brine, 0.5 M HCl, and a saturated sodium bicarbonate solution, and brine. The organic layer was 
dried over sodium sulfate, concentrated in vacuo, and the residue was purified by silica column 
chromatography by eluting with 1 to 3% methanol in dichloromethane. The desired product 5 
was obtained as a red solid (17 mg, 45%). TLC (5% methanol/dichloromethane): Rf = 0.37. MS 
(ESI) m/z (relative intensity, %) = 1127.3 (100) [M+Na]
+
. HRMS (ESI) calcd for 
C49H60N4NaO21S2 [M + Na]
+
 1127.3089, found 1127.3072. 
1
H NMR (500 MHz, CDCl3): 8.06–
8.04 (d, J = 10 Hz, 1H, Dox-2), 7.81–7.78 (t, J = 8 Hz, 1H, Dox-3), 7.44 (s, 1H, Ha), 7.43 (s, 1H, 
Hb), 7.41–7.39 (d, J = 10 Hz, 1H, Dox-1), 6.26 and 6.22 (s, 1H, Hc), 5.54 (s, 1H, Dox-1’), 4.78 (s, 
2H, Dox-14), 4.40–4.13 (m, 5H, Dox-4´, Dox-5´, He), 4.09 (s, 3H, Dox-OCH3), 3.98 & 3.93 (two s, 
6H, Hd & Hd’), 3.88 (m, Dox-3’, He’), 3.79–3.75 (m, 1H, Dox-7), 3.33–3.28 (m, 1H, Dox-10), 3.29–
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3.22 (m, 4H, 2CH2N), 3.07–3.04 (m, 1H, Dox-10), 2.98–2.56 (m, 4H, Hf, Hf’), 2.40–2.37 (m, 1H, 
Dox-8), 2.18–2.14 (m, 1H, Dox-8), 2.00–1.81 (m, 2H, Dox-2’), 1.43 (s, 9H, 3CH3 (N-Boc)), 1.34–
1.32 (m, 3H, Dox-6’) ppm. 
13
C NMR (500 MHz, CDCl3): 187.13, 186.74, 161.05, 156.32, 155.75, 
155.33, 135.73, 133.71, 119.85, 118.39, 111.62, 111.53, 107.40, 100.94, 92.61, 69.12, 67.44, 
65.59, 64.19, 56.68, 56.58, 56.42, 47.29, 46.92, 41.33, 40.40, 35.65, 33.95, 31.76, 31.64, 31.24, 
29.96, 28.37, 17.00 ppm. 
9 G5(FA)n=5.4(Dox)m=5.1 (Scheme 2). This conjugate was prepared by an EDC-based amide 
conjugation of 8 G5(glutaric acid)
5
 with 6 and was characterized as detailed in Supporting 
Information. 
11–12 UCN-PPUX@(Dox)(G5FA) (Figure 3). Details for 10 preparation36 and its 
conjugation with 3 and G5(FA)6 are described in Supporting Information. 
Drug Release Kinetics. Studies of drug release controlled by long UV were performed using 
a Spectroline® UV lamp (XX-15A; peak intensity of emission at 365 nm) as reported by our 
laboratories.
5, 40, 43
 In a representative experiment, 4 was dissolved in 20% aqueous methanol (9.1 
× 10
-5
 M), and exposed to the light at a distance of 5 cm. A series of aliquots were collected as a 
function of irradiation time (t = 0–15 min), and analyzed by UPLC and UV–vis 
spectrophotometry in combination with high resolution mass spectroscopy which was employed 
to confirm the identities of release species. NIR-controlled release studies were performed in 
solutions and KB cells in vitro using a NIR laser (980 nm, power output = 1 W; CNI 
Optoelectronics Tech) following the methods reported from our laboratories.
36, 40
 
Cell Culture: KB cells (human carcinoma) and B16 cells (mouse melanoma) were obtained 
from ATCC. KB cells were grown and maintained in KB media: RPMI 1640 media without folic 
acid (Gibco), supplemented with 10% heat-inactivated fetal bovine serum (Gemini), and 100 
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U/mL penicillin/100 g/mL streptomycin (Gibco). B16 cells were grown in B16 media which 
was the same as KB media with folic acid. 
In Vitro Cytotoxicity: For cell viability assays, KB cells were seeded for 2 days in 96-well 
tissue culture plates at a density of 3000 cells/well. Test compounds: TNB(Dox), dendrimers, 
and UCNs were made as solutions or suspensions (UCNs) in PBS from powder and sonicated in 
a bath sonicator for 30 s prior to dilution in media. Media was then removed from the cells, and 
replaced with the test compounds diluted in KB media at the indicated concentrations and 
incubated at 37 ºC for 30 min. For +UVA samples, cells were exposed to UVA irradiation by 
placing the plate directly under the same UV lamp used above for 10 min. For no UVA samples, 
cells were left at room temperature for 10 min in the dark. Following irradiation, cells were 
incubated for 24 h at 37 °C. The next day, the compound was removed and replaced with fresh 
KB media. Cells were incubated for an additional 4 days and the viability was measured using an 
XTT assay kit (Roche) according to the manufacturer’s protocol. For NIR induced cytotoxicity, 
KB cells were seeded for overnight in 96-well tissue culture plates at a density of 6000 
cells/well. Growth media was removed, and UCN solutions were added to at the indicated 
concentrations n KB media in a volume of 50 L. Cells were incubated at 37 °C for 30 min, and 
then exposed to NIR (980 nm) through a fiber optic as described previously
40
 for 1 h, or left in 
the dark at room temp for 1 h. KB media (150 L) was added to each well resulting in a 1:4 
dilution, and cells were then incubated for 24 h at 37 °C. All concentrations are expressed as the 
initial concentration of UCN. The following day, cells were rinsed with PBS, and fresh media 
was added. Cells were incubated for an additional 4 days at 37 °C and the viability was measured 
as above by XTT. 
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Confocal Microscopy: KB or B16 cells were seeded on an 8-well chambered tissue culture 
coverglass slide at a density of 0.5 × 10
6
 cells/well in KB or B16 media overnight. Media was 
removed and replaced with solutions of 500 g/mL UCNs 11 or 12 in the respective cell culture 
media. Cells were incubated at 37 ºC for 2 h, after which the incubation media was aspirated and 
the cells were washed twice with PBS. Cells were then fixed in 4% paraformaldehyde for 10 
min, and mounted in Prolong Gold© with DAPI (Life Technologies). Confocal images were 
acquired on a Leica inverted confocal microscope (Leica SP5X) at λex = 980 nm; λem = 550 nm, 
650 nm for imaging the UCN core by NIR luminescence. 
Flow Cytometry: For flow analysis, KB cells were trypsinized prior to the experiment, to 
give a suspension in KB media. These cells (2 × 10
5
) were incubated with the indicated 
concentrations of Cy5 labeled UCN conjugates in a total volume of 250 L for 1 h at 37 ºC with 
periodic mixing. After the incubation, cells were spun down and washed twice with FACS buffer 
(0.1% BSA, PBS, 0.1% sodium azide). After the final wash, cells were resuspended in 100 L of 
FACS buffer, and analyzed by flow cytometry on a BD Accuri flow cytometer. The fluorescence 
in FL4 for Cy5 on samples gated for live cells were analyzed, and the % of fluorescent cells was 
taken as the % of cells with fluorescence above that of untreated cells. Similar procedures were 
followed for FA competition studies, except KB cells were preincubated in 50 M or 1 mM for 
15 min at 37 ºC prior to addition of the UCNs, and FA was maintained in the incubation medium 
during the incubation with UCNs. 
Supporting Information. The Supporting Information is available free of charge via the 
Internet at http://pubs.acs.org. Details for the synthesis and characterization of dendrimer and 
UCN nanoconjugates, and their spectral copies. 
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1. Materials and Methods 
Materials 
Reagents and solvents were purchased from commercial suppliers and used as received. 
Those from Sigma-Aldrich include 4,5-dimethoxy-6-nitrobenzaldehyde (purity ≥98%), 2-
mercaptoethanol (≥99%), folic acid dihydrate (98%), 4-nitrophenyl chloroformate (96%), and N-
Boc ethylenediamine (≥98%). Doxorubicin hydrochloride (98.0%) was purchased from 
AvaChem Scientific (San Antonio, TX). Poly(amidoamine) (PAMAM) dendrimer (Generation 
5) G5(NH2)n (theoretical n = 128) was purchased as a solution in methanol (17.5% w/w) from 
Dendritech, Inc. (Midland, MI). Prior to use, it was dialyzed against deionized water in a 
membrane tubing (MWCO 10 kDa), and its number of primary amine branches (experimental, n 
= 114) was determined by potentiometric titration as reported by our laboratories.
1
 
Unless noted otherwise, each reaction for small molecule synthesis was carried out at an 
ambient temperature under a nitrogen atmosphere. Its progress was monitored routinely by thin 
layer chromatography (TLC) on Merck® TLC plates (250 μm thick) and its product was 
detected through illumination with a UV lamp (254 or 365 nm) and by staining with a 
phosphomolybdic acid reagent (20% w/v in ethanol) and/or in an iodine chamber. Reaction 
products were purified by flash column chromatography using silica gel (200-400 mesh). 
Analytical Methods 
Compound homogeneity was assessed by ultraperformance liquid chromatography 
(UPLC
TM
, Waters) on an Acquity Peptide Mapping System equipped with a photodiode array 
detector as reported previously.
2
 Each UPLC sample was prepared in 30–50% aqueous 
acetonitrile at a concentration of 0.1–0.5 mg × mL−1, and injected on a C4 BEH column (100 × 
S3 
 
2.1 mm, 300 Å) at a flow rate of 0.2 mL × min
−1
. A linear gradient method was applied with a 
mixture of eluent A (0.1 TFA v/v% in water) and eluent B (0.1 TFA v/v% in acetonitrile). It 
started with an initial gradient 1% B (0–1.4 min), followed by a linear increase to 80% B (1.4–
13.4 min), a linear decrease to 50% B (13.4–13.8 min) and then to 1% B (13.8–14.4 min) and 
ended with an isocratic condition 1% B (14.4–18 min). 
NMR spectroscopy was performed in Varian NMR spectrometers at either 500 MHz for 
1
H 
nuclei or 100 MHz for 
13
C nuclei. Each NMR sample was prepared in deuterated solvents 
(CDCl3, CD3OD, DMSO-d6) at the concentration of 0.5–2.0 mg/mL as specified in the 
experimental section. Values of chemical shifts () in the NMR spectra were recorded in a 
standard unit (ppm) relative to an internal reference compound ( = 0.00 ppm) such as 
tetramethylsilane (TMS) or 2,2-dimethyl-2-silapentane-5-sulfonate sodium salt (DSS), or were 
corrected with known reference values pertaining to residual solvent peaks. 
UV–vis spectra were recorded in a Perkin Elmer Lambda 20 spectrophotometer. Mass 
spectrometry (ESI MS) for small molecules was performed in a Micromass AutoSpec Ultima 
spectrometer under either a positive or negative ionization mode. Molecular mass (Mr) of 
PAMAM dendrimer conjugates was characterized by matrix assisted laser desorption ionization 
time–of–flight mass spectrometry (MALDI-TOF MS) in a TOfsPec-2E spectrometer (Waters). 
2. Synthesis of 9 G5(FA)n=5.4(Dox)m=5.1 (Scheme 2) 
6 TNB(Dox)(NH2). To a solution of 5 TNB(Dox)(NHBoc) (6.9 mg, 6.3 mol) dissolved in 
anhydrous dichloromethane (1 mL) was added trifluoroacetic acid (TFA, 0.5 mL). The mixture 
was stirred for 15 min at room temp and concentrated in vacuo. The product was used 
immediately without further purification in the next step as described below. 
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9 G5(FA)n=5.4(Dox)m=5.1. To a suspension of 8 G5(Glutaric Acid)
3
 (Mw = 40,200 g mol
-1
; 20 
mg, 0.498 mol) in anhydrous DMF (5 mL) was added 4-dimethylaminopyridine (6 mg, 49.2 
mol), N-hydroxysuccinimide (NHS; 6 mg, 52 mol), and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC; 10 mg, 52 mol). This mixture was stirred at room temp 
for 36 h to preactivate each glutarate residue on the dendrimer surface to its NHS ester prior to 
the addition of a solution of DMF (0.5 mL) that contained a folic acid derivative
4
 FA(NH2) (5 
mg, 10.0 mol) and 6 TNB(Dox)(NH2) (freshly prepared, 6.3 mol). Then triethylamine (27 L, 
194 mol) was added to the reaction mixture to adjust its pH to be slightly basic (pH~9). The 
mixture was stirred at room temp for 36 h in the dark, and the conjugation reaction was quenched 
by adding water (1 mL). The mixture was concentrated to a volume of ~1 mL, and diluted with 
water (8 mL). The solution was concentrated in vacuo, and the residue was loaded into a 
membrane dialysis tubing (MWCO 10 kDa). The dialysis was performed extensively against 
deionized water (2 L), phosphate-buffered saline solution (1 L), and deionized water (3 × 2 L) 
over 48 h. The purified solution in the tubing was collected and lyophilized, yielding 9 
G5(FA)n(Dox)m as a brick red fluffy solid. UPLC analysis: tR = 8.3 min (polymer purity ≥95%); 
UV–vis (PBS pH 7.4): max = 283 ( = 251,878 M
−1
cm
−1
; FA), 355 ( = 94,280 M−1cm−1; FA), 
485 ( = 60,421 M−1cm−1; Dox) nm. MALDI-TOF (m/z): 47,400 g mol−1. 1H NMR (500 MHz, 
DMSO-d6):  8.60 (br s), 8.15–7.91 (strong; br m), 7.65–7.55 (br m), 7.25–7.10 (br m),  8.90 (br 
s), 6.60 (br s), 5.40 (br s), 5.10 (br s), 4.45 (br s), 4.20 (strong; br s), 4.00 (br s), 3.90 (br s), 3.80 
(br s), 3.65 (br s), 3.40 (strong; br s), 3.07 (strong; br s), 2.93 (strong; br s), 2.75 (br s), 2.63 
(strong; br s), 2.54 (strong; br s), 2.42 (strong; br s), 2.38 (br s), 2.18–2.04 (strong; br m), 1.80 
(br s), 1.69 (strong; br s). *Acronyms: br (broad), s (singlet), m (multiplet). 
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The number (valency) of TNB(Dox) (m = 5.1 ± 0.3) attached to G5(FA)n(Dox)m was 
determined on an average basis according to Beer’s law (A = × l × c). In this analysis, a 
standard calibration curve was generated for free Dox ([Dox] = (5.74 × 10
−5
) × A480; R
2
 = 0.993), 
and applied to calculate its valency as a molar ratio of [Dox]/[9] (n = 3). The ligand valency of 
FA (n = 5.4 ± 1.3) was estimated by an NMR integration method in which the proton signal for 
FA at  6.8–7.0 ppm (2H) was compared to a reference group of HNC(=O)CH2CH2CH2C(=O) at 
 1.71 ppm (108 glutarate residues per dendrimer3). 
3. Synthesis of UCN-PPIX@(Dox)(G5FA) (Figure 3) 
Upconversion Nanocrystal (-NaYF4: 20%Yb, 2%Er). UCN (NaYF4: 20%Yb, 2%Er) was 
prepared by a hot injection method as reported earlier.
4, 5
 In brief, a mixture of octadecene (10 
mL), oleic acid (9.7 mL) and sodium oleate (288 mg) was heated at 290 C and followed by a 
dropwise injection of a preheated (100 C) mixture of oleic acid (2.5 mL) and octadecene (2.5 
mL) that contained CF3COONa (350 mg, 2.5 mmol), (CF3COO)3Y (333.8 mg, 0.78 mmol), 
(CF3COO)3Yb (102 mg, 0.2 mmol ), and (CF3COO)3Er (10.2 mg, 0.02 mmol) under dry 
nitrogen. After its injection, the final mixture was heated to 330C and stirred further for 20 min. 
To isolate the product, the hot mixture was cooled to room temp, and ethanol was added to 
precipitate formed UCNs. The desired UCN (β-NaYF4: 20%Yb, 2%Er) was collected by 
centrifugation and rinsed thoroughly with chloroform and methanol. 
10 UCN-PPIX. Details for the preparation of UCN-PPIX are described recently in our 
report.
6
 The UCN (NaYF4: 20%Yb, 2%Er) (mean diameter = 42 nm) prepared above was coated 
with a siloxane polymer layer with 3–5 nm in thickness that contained protoporphyrin IX (PPIX) 
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by a nonionic water-in-oil microemulsion method. This method led to the incorporation of PPIX 
at a composition rate of 3.27% (w/w) in the shell layer of UCN-PPIX. 
11 UCN-PPIX@(Dox). 4 TNB(Dox)(4-NP) (2.0 mg; 1.85 mol) was dissolved in methanol 
(1.0 mL; 1.85 mM). An aliquot (0.02 mL) was taken from this solution, diluted with PBS pH 7.4 
(1.0 mL), and labeled as “aliquot 1”. This aliquot solution served as a reference to calculate the 
amount of TNB(Dox)(4-NP) that reacted with UCN-PPIX. The remaining solution (0.98 mL) 
was used next step as follows. 
To UCN-PPIX (20 mg) dispersed in acetonitrile (1 mL) was added 0.1 M NaOH (0.1 mL). 
This mixture was shaken for 5 min and spun down at 5,500 rpm for 15 min. The supernatant was 
carefully removed, and the pellet was rinsed with acetonitrile (1 mL) by centrifugation. This 
pellet was dispersed in methanol (0.5 mL) and mixed with the remaining solution (0.98 mL) of 4 
TNB(Dox)(4-NP) prepared above. The mixture was sonicated for 30 s and shaken at room temp 
for 24 h in the dark. After reaction, the mixture was spun at 5,500 rpm for 15 min. An aliquot of 
0.02 mL was taken from the supernatant layer, diluted with PBS pH 7.4 (1.0 mL), and labeled as 
“aliquot 2”. The remaining supernatant was carefully removed, and the pellet was rinsed three 
times with 50% acetonitrile/methanol (1.5 mL each) by centrifugation (5,500 rpm, 20 min). The 
pellet was collected and dried under nitrogen atmosphere, affording UCN-PPIX@(Dox) as a pale 
red purple powder (19.2 mg). The amount of TNB(Dox) covalently attached to the shell surface 
of UCN-PPIX was calculated as 0.892 mg (44.6% conjugation yield) from the spectroscopic 
analysis of the two aliquots in which each aliquot was analyzed for its absorbance at max (400 
nm) selected to quantify 4-nitrophenol (4-NP) generated. UV–vis (1.0 mg/mL; methanol): max = 
445–512 nm (Dox), 408 nm (protoporphyrin IX), 255 nm. 
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12 UCN-PPIX@(Dox)(G5FA). First, G5(FA)6—a fifth generation (G5) PAMAM dendrimer 
conjugated with folic acid (average 6 FA per dendrimer nanoparticle; MW = 38,600 g mol
−1
)
4—
was preactivated for conjugation with UCN-PPIX@(Dox). Thus, G5(FA)6 (3 mg, 77.7 nmol) 
was dissolved in DMF (0.6 mL) that contained NHS (1.8 mg, 15.5 mol) and 4-
dimethylaminopyridine (DMAP; 1.9 mg, 15.5 mol). To this solution was added EDC (3.0 mg, 
15.5 mol) as a solid, and the mixture was stirred for 30 min at room temp. An aliquot (0.015 
ml) of the activated solution was taken out, diluted with PBS, pH 7.4 (1.0 mL), and labeled as 
“aliquot 3”. 
The solution (0.585 mL) of the preactivated G5(FA)6 above was added to UCN-
PPIX@(Dox) (12 mg) in an Eppendorf vial. The mixture was shaken at room temp for 48  in the 
dark, and centrifuged at 5,500 rpm for 20 min. The pale pink supernatant solution was carefully 
removed, and an “aliquot 4” (0.015 mL) was taken out from the supernatant, and mixed with 
PBS, pH 7.4 (1.0 mL) for UV-vis analysis. The pellet was suspended in methanol (1.0 mL) and 
sonicated for 10 sec before centrifugation. This rinsing process was repeated with methanol, 50% 
aqueous methanol, and methanol. The pellet (reddish brown) was collected, and dried under 
nitrogen atmosphere (12.2 mg). The amount of G5(FA)6 conjugated was calculated by 
spectrophotometric analysis (absorption at 275 nm for FA) between “aliquot 3” and “aliquot 4”, 
each taken before and after the conjugation reaction. This analysis led to 12.3% of G5(FA)6 
attached which is equivalent to 3.1% (w/w) of dendrimer to UCN-PPIX@(Dox)(G5FA). UV–vis 
(1.0 mg/mL; methanol): max = 285, 220 nm (G5(FA)6). 
Cy5-labeled UCN Conjugates (11, 12). To 12 UCN-PPIX@(Dox)(G5FA) (0.4 mg) 
weighed in an Eppendorf vial was added 0.1 mg of sulfo-cyanine5 NHS ester (Molecular 
Probes®) dissolved in anhydrous DMF (0.3 mL) and followed by the addition of N,N-
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diisopropyl N-ethylamine (0.03 mL). This mixture was shaken at room temp for 12 h in the dark. 
After the reaction, it was centrifuged at 5,500 rpm for 20 min, and its supernatant solution was 
carefully removed. The remaining UCN pellet was rinsed multiple times with methanol (1.0 
mL), 50% aqueous methanol, and then methanol. It was collected and dried under nitrogen, 
yielding Cy5-labeled 12 as a blue powder (0.34 mg). UV–vis spectroscopy: max = 670 nm 
(methanol). Cy5-labeled 11 UCN-PPIX@(Dox) was prepared in the same manner. 
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4. Table S1. Summary of molecular properties and valency of 9 G5(FA)n=5.4(Dox)m=5.1 
Dendrimer 
Conjugate 
Mr (g mol
-1
)
 a
 UV–vis (max, nm) Valency
c 
NMR UV–vis 
G5(NH2)114 27,600 (1.09
b
)  - - 
8 G5(GA)n=108 40,200  n = 108
3
 - 
9 G5(FA)n(Dox)m 47,400 283, 355 (FA); 480 
(Dox) 
n = 5.4 (±1.3) m = 5.1 (±0.3) 
a 
molecular weight of peak maxima (MALDI–TOF MS), g mol-1; b polydispersity index (PDI) = 
Mw/Mn (GPC); 
c 
mean (±SD) 
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5. Figure S1, S2 
 
 
Figure S1. UPLC traces of folic acid (FA) and 5 TNB(Dox)(NHBoc) (A), and dendrimer 
conjugates G5(FA)6, 9 G5(FA)5.4(Dox)5.1 (B); UV-vis spectra of FA and 5 TNB(Dox)(NHBoc) 
(C), G5(FA)6 (D) and 9 G5(FA)5.4(Dox)5.1 (E). For UV–vis spectrometry, each conjugate was 
measured in PBS pH 7.4. 
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Figure S2. Poissonian distribution of dendrimer species with regards to the valency of FA and 
Dox in 9 G5(FA)n(Dox)m with the mean value of n = 5.4 (FA) and m = 5.1 (Dox). Dendrimer 
species with variable valency (n, m) are plotted as % fractional populations. 
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6. Copies of Spectral Data for 3, 4, 5, and 9 
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